PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer
NCT04219904 is a phase early 1 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is active and no longer recruiting. It studies Gadobutrol in Stage IA Cervical Cancer, Stage IA1 Cervical Cancer and 5 more conditions. The registry lists an enrollment of 25 participants at 1 site in 1 country. The registry lists a start date of 7 Sept 2018 and a primary completion date of 30 Sept 2027.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04219904 |
| Status | Active not recruiting |
| Phase | Phase Early 1 |
| Study type | Interventional trial |
| Lead sponsor | M.D. Anderson Cancer Center |
| Enrollment | 25 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Stage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer and 1 more condition |
| Drugs | Gadobutrol |
| Start | 7 Sept 2018 |
| Primary completion | 30 Sept 2027 |
| Study completion | 30 Sept 2027 |
| Last update posted | 10 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Sanaz Javadi
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- M D Anderson Cancer Center
Houston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04219904
Each answer restates registry values shown on this page.
What is NCT04219904?
NCT04219904 is a phase early 1 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Gadobutrol in Stage IA Cervical Cancer, Stage IA1 Cervical Cancer and 5 more conditions.
Is NCT04219904 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT04219904?
The registry names Sanaz Javadi (principal investigator, M.D. Anderson Cancer Center) as the overall official.
Where does NCT04219904 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04219904 study?
The registered drug and biological interventions are Gadobutrol.
When is NCT04219904 expected to complete?
The registry lists a primary completion date of 30 Sept 2027 and a study completion date of 30 Sept 2027. The sponsor last updated the record on 10 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.